# Phibro Animal Health Corp: Form 10-Q for the period ended Mar 31, 2024

- Company: [Phibro Animal Health Corp](/companies/pahc.md) (CIK 1069899)
- Form: 10-Q
- Filed: 2024-05-08
- Accepted by EDGAR: May 8, 2024, 16:10 ET
- Period: 2024-03-31
- Accession: 0001558370-24-007340
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007340/pahc-20240331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1069899/000155837024007340/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-01-01 to 2024-03-31 | $263.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-07-01 to 2024-03-31 | $744.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-01-01 to 2024-03-31 | $183.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2023-07-01 to 2024-03-31 | $518.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-01-01 to 2024-03-31 | $79.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-07-01 to 2024-03-31 | $225.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2024-01-01 to 2024-03-31 | $59.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-07-01 to 2024-03-31 | $191.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-01-01 to 2024-03-31 | $19.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-07-01 to 2024-03-31 | $34.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-01-01 to 2024-03-31 | $5.6m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-07-01 to 2024-03-31 | $17.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2024-01-01 to 2024-03-31 | $4.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-07-01 to 2024-03-31 | $2.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-01-01 to 2024-03-31 | $8.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-07-01 to 2024-03-31 | $1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-07-01 to 2024-03-31 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-01-01 to 2024-03-31 | $0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-07-01 to 2024-03-31 | $0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-01-01 to 2024-03-31 | 40,520,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-07-01 to 2024-03-31 | 40,509,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-07-01 to 2024-03-31 | $59.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-07-01 to 2024-03-31 | $28.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2023-07-01 to 2024-03-31 | $14.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2024-03-31 | $50.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-03-31 | $597.2m | us-gaap:AssetsCurrent |
| Total assets | at 2024-03-31 | $979.0m | us-gaap:Assets |
| Current liabilities | at 2024-03-31 | $189.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-03-31 | $708.9m | us-gaap:Liabilities |
| Long-term debt | at 2024-03-31 | $291.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-03-31 | $29.8m | us-gaap:DebtCurrent |
| Short-term borrowings | at 2024-03-31 | $1.9m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2024-03-31 | $270.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 59,192 characters.

### Introduction

Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” in Item 1A of our Annual Report and “Forward-Looking Statements.”

### Overview of our business

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

### Agreement to acquire an MFA product portfolio and related assets

In April 2024, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc. to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets. The purchase price is $350,000 subject to certain adjustments set forth in the Purchase Agreement, payable in cash at closing. The closing of the transaction is subject to certain customary conditions.

We plan to finance the transaction with approximately $325,000 of new debt and, to the extent necessary, balance sheet cash. In connection with the Purchase Agreement, we entered into a debt commitment letter pursuant to which certain financial institutions have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325,000. The funding of the incremental first lien term loan facility is contingent on the satisfaction of certain customary conditions.

### Armed Conflicts

#### Hamas and Israel

On October 7, 2023, Hamas militants crossed into Israel from Gaza in a large-scale, surprise terrorist attack. Hamas terrorists invaded Israel, first firing rockets into the country and then carrying out attacks inflicting mass casualties with hundreds more taken hostage. In order to provide immediate assistance to the victims of the attacks and their families, we and our employees provided monetary donations that were distributed to charities that offered relief services, welfare, equipment, food and other necessities.

We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of March 31, 2024, we had approximately 500 employees located in Israel. While we initially had some disruption to our operations at the onset of the Israel-Hamas conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. A significant escalation of the tensions in Israel occurred on April 13, 2024, when Iran launched more than 300 drones and missiles against Israel, but we had no material disruption to our business. While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years.

The prolonged continuation or escalation of this conflict may trigger bans, economic and other sanctions, as well as broader military conflict, which could include neighboring nations. The potential impact of the current conflict, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 28% of our consolidated assets as of March 31, 2024, and 21% of our consolidated net sales for the nine months ended March 31, 2024.

#### Russia and Ukraine

In response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and technical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia.

Since the conflict began, the United States and other North Atlantic Treaty Organization (“NATO”) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the 12 months ended March 31, 2024, represented approximately 1% of consolidated net sales.

We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations.

### Regulatory developments

In April 2016, the Food and Drug Administration (“FDA”) began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (“NOOH”), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDA’s Center for Veterinary Medicine (“CVM”) inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method.

In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the extensive research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting residues of carbadox. The FDA also provided notice in the Federal Register proposing to withdraw approval of all new animal drug applications (NADAs) providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVM’s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is taking the next steps to continue to defend swine producers’ ability to use Mecadox. We have formally requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the 12 months ended March 31, 2024 were approximately $20.0 million. As of the date of the filing of this Quarterly Report on Form 10-Q, Mecadox continues to be available for use by swine producers. For additional information, see also “Business — Compliance with Government Regulation — United States — Carbadox”; and “Business — Compliance with Government Regulation — Global Policy and Guidance” in Item 1 of our Annual Report.

### Analysis of the consolidated statements of operations

### Summary Results of Operations

*(in thousands, except per share amounts and percentages)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ ​ | ​ ​ ​ Three Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ | ​ ​ ​ Nine Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | ---: | ---: | ---: | --- | --- | --- | ---: | ---: | ---: | --- | --- |
| Net sales |  | $263,223 **​** | $245,673 | $17,550 |  | 7% | ​ | $744,515 | $722,840 | $21,675 |  | 3% |
| Gross profit | ​ | 79,600 ​ | 75,540 ​ | 4,060 | ​ | 5% | ​ | 225,942 ​ | 221,571 ​ | 4,371 | ​ | 2% |
| Selling, general and administrative expenses | ​ | 59,676 ​ | 56,987 ​ | 2,689 | ​ | 5% | ​ | 191,043 ​ | 173,490 ​ | 17,553 | ​ | 10% |
| Operating income | ​ | 19,924 ​ | 18,553 ​ | 1,371 | ​ | 7% | ​ | 34,899 ​ | 48,081 ​ | (13,182) | ​ | \* ​ |
| Interest expense, net | ​ | 4,575 ​ | 3,871 ​ | 704 | ​ | 18% | ​ | 13,798 ​ | 10,822 ​ | 2,976 | ​ | 27% |
| Foreign currency losses (gains), net | ​ | 2,427 ​ | (422) ​ | 2,849 | ​ | \* ​ | ​ | 16,593 ​ | 4,629 ​ | 11,964 | ​ | \* ​ |
| Income before income taxes | ​ | 12,922 ​ | 15,104 ​ | (2,182) | ​ | (14)% | ​ | 4,508 ​ | 32,630 ​ | (28,122) | ​ | \* ​ |
| Provision for income taxes | ​ | 4,517 ​ | 5,062 ​ | (545) | ​ | (11)% | ​ | 2,844 ​ | 11,522 ​ | (8,678) | ​ | \* ​ |
| Net income | ​ | $8,405 ​ | $10,042 ​ | $(1,637) | ​ | (16)% | ​ | $1,664 ​ | $21,108 ​ | $(19,444) | ​ | \* ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Net income per share | ​ | ​ | ​ ​ | ​ |  | ​ ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ ​ |
| Basic | ​ | $0.21 ​ | $0.25 ​ | $(0.04) | ​ | (16)% | ​ | $0.04 ​ | $0.52 ​ | $(0.48) | ​ | \* ​ |
| Diluted | ​ | $0.21 ​ | $0.25 ​ | $(0.04) | ​ | (16)% | ​ | $0.04 ​ | $0.52 ​ | $(0.48) | ​ | \* ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Weighted average number of shares outstanding | ​ | ​ | ​ ​ |  | ​ | ​ ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Basic | ​ | 40,504 ​ | 40,504 ​ |  | ​ | ​ ​ | ​ | 40,504 ​ | 40,504 ​ |  | ​ | ​ ​ |
| Diluted | ​ | ​ 40,520 ​ | ​ 40,504 ​ | ​ ​ | ​ | ​ ​ | ​ | ​ 40,509 ​ | ​ 40,504 ​ | ​ ​ | ​ | ​ ​ |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Ratio to net sales | ​ | ​ | ​ ​ |  | ​ | ​ ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Gross profit | ​ | 30.2% | 30.7% |  | ​ | ​ ​ | ​ | 30.3% | 30.7% |  | ​ | ​ ​ |
| Selling, general and administrative expenses | ​ | 22.7% | 23.2% |  | ​ | ​ ​ | ​ | 25.7% | 24.0% |  | ​ | ​ ​ |
| Operating income | ​ | 7.6% | 7.6% |  | ​ | ​ ​ | ​ | 4.7% | 6.7% |  | ​ | ​ ​ |
| Income before income taxes | ​ | 4.9% | 6.1% |  | ​ | ​ ​ | ​ | 0.6% | 4.5% |  | ​ | ​ ​ |
| Net income | ​ | 3.2% | 4.1% |  | ​ | ​ ​ | ​ | 0.2% | 2.9% | ​ | ​ | ​ ​ |
| Effective tax rate | ​ | 35.0% | 33.5% |  | ​ | ​ ​ | ​ | 63.1% | 35.3% |  | ​ | ​ ​ |

Certain amounts and percentages may reflect rounding adjustments.

\* Calculation not meaningful

### Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA

We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures.”

Segment net sales and Adjusted EBITDA:

*(in thousands, except percentages)*

| ​ ​ For the Periods Ended March 31 Net sales | ​ ​ ​ | ​ ​ ​ Three Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ Nine Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | ---: | ---: | ---: | --- | ---: | --- | ---: | ---: | ---: | --- | ---: |
| MFAs and other | ​ | $108,216 ​ | $93,217 ​ | $14,999 |  | 16% | ​ | $304,261 ​ | $283,186 ​ | $21,075 | ​ | 7% |
| Nutritional specialties | ​ | 40,194 ​ | 45,016 ​ | (4,822) |  | (11)% | ​ | 121,840 ​ | 127,926 ​ | (6,086) | ​ | (5)% |
| Vaccines | ​ | 32,923 ​ | 26,201 ​ | 6,722 |  | 26% | ​ | 88,866 ​ | 71,984 ​ | 16,882 | ​ | 23% |
| Animal Health | ​ | 181,333 ​ | 164,434 ​ | 16,899 |  | 10% | ​ | 514,967 ​ | 483,096 ​ | 31,871 | ​ | 7% |
| Mineral Nutrition | ​ | 64,228 ​ | 62,922 ​ | 1,306 |  | 2% | ​ | 181,601 ​ | 184,212 ​ | (2,611) | ​ | (1)% |
| Performance Products | ​ | 17,662 ​ | 18,317 ​ | (655) |  | (4)% | ​ | 47,947 ​ | 55,532 ​ | (7,585) | ​ | (14)% |
| Total | ​ | $263,223 ​ | $245,673 ​ | $17,550 |  | 7% | ​ | $744,515 ​ | $722,840 ​ | $21,675 | ​ | 3% |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| **Adjusted EBITDA** | ​ | ​ | ​ |  |  | ​ | ​ | ​ | ​ |  | ​ | ​ ​ |
| Animal Health | ​ | $36,524 ​ | $34,217 ​ | $2,307 |  | 7% | ​ | $104,317 ​ | $98,240 ​ | $6,077 | ​ | 6% |
| Mineral Nutrition | ​ | 4,665 ​ | 3,859 ​ | 806 |  | 21% | ​ | 11,053 ​ | 13,555 ​ | (2,502) | ​ | (18)% |
| Performance Products | ​ | 2,371 ​ | 2,413 ​ | (42) |  | (2)% | ​ | 4,597 ​ | 7,069 ​ | (2,472) | ​ | (35)% |
| Corporate | ​ | (13,856) ​ | (13,122) ​ | (734) |  | 6% | ​ | (42,160) ​ | (38,451) ​ | (3,709) | ​ | 10% |
| Total | ​ | $29,704 ​ | $27,367 ​ | $2,337 |  | 9% | ​ | $77,807 ​ | $80,413 ​ | $(2,606) | ​ | (3)% |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Adjusted EBITDA as a percentage of segment net sales | ​ | ​ | ​ ​ |  |  | ​ | ​ | ​ | ​ ​ |  | ​ | ​ ​ |
| Animal Health | ​ | 20.1% | 20.8% |  |  | ​ | ​ | 20.3% | 20.3% |  | ​ | ​ ​ |
| Mineral Nutrition | ​ | 7.3% | 6.1% |  |  | ​ | ​ | 6.1% | 7.4% |  | ​ | ​ ​ |
| Performance Products | ​ | 13.4% | 13.2% |  |  | ​ | ​ | 9.6% | 12.7% |  | ​ | ​ ​ |
| Corporate (1) | ​ | (5.3)% | (5.3)% |  |  | ​ | ​ | (5.7)% | (5.3)% |  | ​ | ​ ​ |
| Total (1) | ​ | 11.3% | 11.1% |  |  | ​ | ​ | 10.5% | 11.1% |  | ​ | ​ ​ |

(1) Reflects ratio to total net sales

The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

*(in thousands, except percentages)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ | ​ ​ Three Months 2024 | ​ | ​ ​ 2023 | ​ | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ Nine Months 2024 | ​ | ​ ​ 2023 | ​ | ​ ​ Change | ​ | ​ ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net income | ​ | $8,405 | ​ | $10,042 | ​ | $(1,637) | **​** | (16)% | ​ | $1,664 | ​ | $21,108 | ​ | $(19,444) |  | \* ​ |
| Interest expense, net | ​ | ​ 4,575 | ​ | ​ 3,871 | ​ | ​ 704 | ​ | 18% | ​ | ​ 13,798 | ​ | ​ 10,822 | ​ | ​ 2,976 | ​ | 27% |
| Provision for income taxes | ​ | ​ 4,517 | ​ | ​ 5,062 | ​ | ​ (545) | ​ | (11)% | ​ | ​ 2,844 | ​ | ​ 11,522 | ​ | ​ (8,678) | ​ | \* ​ |
| Depreciation and amortization | ​ | ​ 9,196 | ​ | ​ 8,489 | ​ | ​ 707 | ​ | 8% | ​ | ​ 26,977 | ​ | ​ 25,438 | ​ | ​ 1,539 | ​ | 6% |
| EBITDA | ​ | ​ 26,693 | ​ | ​ 27,464 | ​ | ​ (771) | ​ | (3)% | ​ | ​ 45,283 | ​ | ​ 68,890 | ​ | ​ (23,607) | ​ | (34)% |
| Acquisition-related cost of goods sold | ​ | ​ 211 | ​ | ​ — | ​ | ​ 211 | ​ | \* ​ | ​ | ​ 521 | ​ | ​ — | ​ | ​ 521 | ​ | \* ​ |
| Acquisition-related other | ​ | ​ 512 | ​ | ​ — | ​ | ​ 512 | ​ | \* ​ | ​ | ​ 512 | ​ | ​ — | ​ | ​ 512 | ​ | \* ​ |
| Pension settlement cost |  | ​ — |  | ​ — |  | ​ — |  | \* ​ | ​ | ​ 10,674 |  | ​ — |  | ​ 10,674 | ​ | \* ​ |
| Brazil employment taxes | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | \* ​ | ​ | ​ 4,202 | ​ | ​ — | ​ | ​ 4,202 | ​ | \* ​ |
| Insurance proceeds | ​ | ​ (274) | ​ | ​ — | ​ | ​ (274) | ​ | \* ​ | ​ | ​ (274) | ​ | ​ — | ​ | ​ (274) | ​ | \* ​ |
| Stock-based compensation | ​ | ​ 135 | ​ | ​ — | ​ | ​ 135 |  | \* ​ | ​ | ​ 296 | ​ | ​ — | ​ | ​ 296 | ​ | \* ​ |
| Environmental remediation costs | ​ | ​ — | ​ | ​ 325 | ​ | ​ (325) |  | \* ​ | ​ | ​ — | ​ | ​ 6,894 | ​ | ​ (6,894) | ​ | \* ​ |
| Foreign currency losses (gains), net | ​ | ​ 2,427 |  | ​ (422) |  | ​ 2,849 |  | \* ​ | ​ | ​ 16,593 |  | ​ 4,629 |  | ​ 11,964 | ​ | \* ​ |
| Adjusted EBITDA | ​ | $29,704 | ​ | $27,367 | ​ | $2,337 |  | 9% | ​ | $77,807 | ​ | $80,413 | ​ | $(2,606) | ​ | (3)% |

Certain amounts may reflect rounding adjustments.

\* Calculation not meaningful

### Adjusted net income

We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. See “—General description of non-GAAP financial measures.” The table below sets forth a reconciliation of net income, as reported under GAAP, to adjusted net income:

*(in thousands, except per share amounts and percentages)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ ​ | ​ ​ ​ Three Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ ​ | ​ ​ ​ Nine Months 2024 | ​ ​ ​ 2023 | ​ ​ Change | ​ | ​ ​ |
| --- | --- | ---: | ---: | ---: | --- | --- | ---: | ---: | ---: | --- | --- |
| Net income | ​ | $8,405 ​ | $10,042 ​ | $(1,637) |  | (16)% | $1,664 ​ | $21,108 ​ | $(19,444) |  | \* ​ |
| Acquisition-related intangible amortization (1) | ​ | 1,670 ​ | 1,659 ​ | 11 |  | 1% | 5,014 ​ | 4,973 ​ | 41 |  | 1% |
| Acquisition-related intangible amortization (2) | ​ | 756 ​ | 761 ​ | (5) |  | (1)% | 2,325 ​ | 2,281 ​ | 44 |  | 2% |
| Acquisition-related cost of goods sold (1) | ​ | ​ 211 ​ | ​ — ​ | ​ 211 | ​ | \* ​ | ​ 521 ​ | ​ — ​ | ​ 521 | ​ | \* ​ |
| Acquisition-related other (2) | ​ | ​ 512 ​ | ​ — ​ | ​ 512 | ​ | \* ​ | ​ 512 ​ | ​ — ​ | ​ 512 | ​ | \* ​ |
| Pension settlement cost (2) | ​ | ​ — ​ | ​ — ​ | ​ — | ​ | \* ​ | ​ 10,674 ​ | ​ — ​ | ​ 10,674 |  | \* ​ |
| Brazil employment taxes (2) | ​ | ​ — ​ | ​ — ​ | ​ — | ​ | \* ​ | ​ 4,202 ​ | ​ — ​ | ​ 4,202 | ​ | \* ​ |
| Insurance proceeds (2) | ​ | ​ (274) ​ | ​ — ​ | ​ (274) | ​ | \* ​ | ​ (274) ​ | ​ — ​ | ​ (274) | ​ | \* ​ |
| Stock-based compensation (2) | ​ | ​ 135 ​ | ​ — ​ | ​ 135 | ​ | \* ​ | ​ 296 ​ | ​ — ​ | ​ 296 | ​ | \* ​ |
| Environmental remediation costs (2) | ​ | ​ — ​ | ​ 325 ​ | ​ (325) | ​ | \* ​ | ​ — ​ | ​ 6,894 ​ | ​ (6,894) | ​ | \* ​ |
| Foreign currency losses (gains), net (3) | ​ | 2,427 ​ | (422) ​ | 2,849 |  | \* ​ | 16,593 ​ | 4,629 ​ | 11,964 |  | \* ​ |
| Adjustments to income taxes (4) | ​ | (1,145) ​ | (722) ​ | (423) |  | \* ​ | (9,830) ​ | (6,131) ​ | (3,699) |  | \* ​ |
| Adjusted net income | ​ | $12,697 ​ | $11,643 ​ | $1,054 |  | 9% | $31,697 ​ | $33,754 ​ | $(2,057) |  | (6)% |
| ​ | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Statement of Operations Line Items - adjusted | ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ | ​ | ​ ​ |
| Adjusted cost of goods sold (1) | ​ | $181,742 ​ | $168,474 ​ | $13,268 |  | 8% | $513,038 ​ | $496,296 ​ | $16,742 |  | 3% |
| Adjusted gross profit | ​ | 81,481 ​ | 77,199 ​ | 4,282 |  | 6% | 231,477 ​ | 226,544 ​ | 4,933 | ​ | 2% |
| Adjusted selling, general and administrative (2) | ​ | 58,546 ​ | 55,901 ​ | 2,645 |  | 5% | 173,308 ​ | 164,315 ​ | 8,993 |  | 5% |
| Adjusted interest expense, net | ​ | 4,576 ​ | 3,871 ​ | 705 |  | 18% | 13,798 ​ | 10,822 ​ | 2,976 |  | 27% |
| Adjusted income before income taxes | ​ | 18,359 ​ | 17,427 ​ | 932 |  | 5% | 44,371 ​ | 51,407 ​ | (7,036) |  | (14)% |
| Adjusted provision for income taxes (4) | ​ | 5,662 ​ | 5,784 ​ | (122) |  | (2)% | 12,674 ​ | 17,653 ​ | (4,979) |  | (28)% |
| Adjusted net income | ​ | $12,697 ​ | $11,643 ​ | $1,054 |  | 9% | $31,697 ​ | $33,754 ​ | $(2,057) |  | (6)% |
| ​ | ​ | ​ ​ | ​ ​ | ​ |  | ​ | ​ ​ | ​ ​ |  |  | ​ |
| Adjusted net income per share | ​ | ​ ​ | ​ ​ | ​ |  | ​ | ​ ​ | ​ ​ |  |  | ​ |
| diluted | ​ | $0.31 ​ | $0.29 ​ | $0.02 |  | 9% | $0.78 ​ | $0.83 ​ | $(0.05) |  | (6)% |
| ​ | ​ | ​ ​ | ​ ​ |  |  | ​ | ​ ​ | ​ ​ |  |  | ​ |
| Weighted average common shares outstanding | ​ | ​ ​ | ​ ​ |  |  | ​ | ​ ​ | ​ ​ |  |  | ​ |
| diluted | ​ | 40,520 ​ | 40,504 ​ |  |  | ​ | 40,509 ​ | 40,504 ​ |  |  | ​ |
| ​ | ​ | ​ ​ | ​ ​ |  |  | ​ | ​ ​ | ​ ​ |  |  | ​ ​ |
| Ratio to net sales | ​ | ​ ​ | ​ ​ |  |  | ​ | ​ ​ | ​ ​ |  |  | ​ |
| Adjusted gross profit | ​ | 31.0% | 31.4% | ​ |  | ​ | 31.1% | 31.3% |  |  | ​ |
| Adjusted selling, general and administrative | ​ | 22.2% | 22.8% |  |  | ​ | 23.3% | 22.7% |  |  | ​ |
| Adjusted income before income taxes | ​ | 7.0% | 7.1% |  |  | ​ | 6.0% | 7.1% |  |  | ​ |
| Adjusted net income | ​ | 4.8% | 4.7% |  |  | ​ | 4.3% | 4.7% |  |  | ​ |
| Adjusted effective tax rate | ​ | 30.8% | 33.2% |  |  | ​ | 28.6% | 34.3% |  |  | ​ |

Certain amounts and percentages may reflect rounding adjustments.

\* Calculation not meaningful

(1) Adjusted cost of goods sold excludes acquisition-related intangible amortization and acquisition-related cost of goods sold

(2) Adjusted selling, general and administrative excludes acquisition-related intangible amortization, pension settlement cost, Brazil employment taxes, acquisition-related other, insurance proceeds, stock-based compensation and environmental remediation costs

(3) Foreign currency losses (gains), net are excluded from adjusted net income

(4) Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments and certain income tax items

### Comparison of three months ended March 31, 2024 and 2023

### Net sales

Net sales of $263.2 million for the three months ended March 31, 2024, increased $17.6 million, or 7%, as compared to the three months ended March 31, 2023. Animal Health and Mineral Nutrition increased $16.9 million and $1.3 million, respectively. Performance Products decreased $0.7 million.

#### Animal Health

Net sales of $181.3 million for the three months ended March 31, 2024, increased $16.9 million, or 10%. Net sales of MFAs and other increased $15.0 million, or 16%, due to increased demand for our MFAs in both domestic and international regions. Net sales of nutritional specialty products decreased $4.8 million, or 11%, mostly due to lower demand for microbial and dairy products. Net sales of vaccines increased $6.7 million, or 26%, primarily due to poultry product introductions in Latin America, plus an increase in both domestic and international demand.

#### Mineral Nutrition

Net sales of $64.2 million for the three months ended March 31, 2024, increased $1.3 million, or 2%, due to increased sales volume, partially offset by decreased average selling price.

#### Performance Products

Net sales of $17.7 million for the three months ended March 31, 2024, decreased $0.7 million, or 4%, due to a decrease in demand for personal care product ingredients and industrial chemicals.

### Gross profit

Gross profit of $79.6 million for the three months ended March 31, 2024, increased $4.1 million, or 5%, as compared to the three months ended March 31, 2023. Gross margin decreased 50 basis points to 30.2% of net sales for the three months ended March 31, 2024, as compared to 30.7% for the three months ended March 31, 2023, due to unfavorable product mix.

Animal Health gross profit increased $3.5 million, primarily driven by higher sales volume, partially offset by unfavorable product mix. Mineral Nutrition gross profit increased $0.9 million, driven by increased sales volumes. Performance Products gross profit was comparable to the prior year’s quarter. Acquisition-related cost of goods sold reduced gross profit by $0.2 million.

### Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of $59.7 million for the three months ended March 31, 2024, increased $2.7 million, or 5%, as compared to the three months ended March 31, 2023. SG&A for the three months ended March 31, 2024, included $0.5 million in acquisition-related costs and $0.1 million of stock-based compensation, partially offset by a gain from insurance proceeds of $0.3 million. SG&A for the three months ended March 31, 2023, included $0.3 million of environmental remediation costs. Excluding these items, SG&A increased $2.6 million, or 5%.

Animal Health SG&A increased $2.0 million, primarily due to an increase in employee-related costs to support increased demand and new product launches in Latin America. Mineral Nutrition and Performance Products SG&A was comparable to the prior year. Corporate costs increased by $0.7 million, due to an increase in employee-related costs.

### Interest expense, net

Interest expense, net of $4.6 million for the three months ended March 31, 2024, increased by $0.7 million, as compared to the three months ended March 31, 2023, as a result of higher variable interest rates and increased debt levels.

### Foreign currency losses (gains), net

Foreign currency losses, net for the three months ended March 31, 2024, were $2.4 million, as compared to $0.4 million of net gains for the three months ended March 31, 2023. Current period losses were driven by fluctuations in certain currencies related to the U.S. dollar.

### Provision for income taxes

The provision for income taxes was $4.5 million and $5.1 million for the three months ended March 31, 2024 and 2023, respectively. The effective income tax rates were 35.0% and 33.5% for the three months ended March 31, 2024 and 2023, respectively. The effective income tax rate for the three months ended March 31, 2024, increased due to the relatively greater effect of certain items such as Global Intangible Low-Taxed Income (“GILTI”) on reduced pre-tax income.

### Net income

Net income of $8.4 million for the three months ended March 31, 2024, decreased $1.6 million, as compared to net income of $10.0 million for the three months ended March 31, 2023. Operating income increased $1.4 million, driven by favorable gross profit, partially offset by higher SG&A. Gross profit increased primarily as a result of higher product demand in the Animal Health segment. SG&A increased due to higher employee-related costs. Interest expense, net increased $0.7 million and foreign currency exchange resulted in increased losses of $2.8 million. This was partially offset by a $0.5 million decrease in income tax expense.

### Adjusted EBITDA

Adjusted EBITDA of $29.7 million for the three months ended March 31, 2024, increased $2.3 million, or 9%, as compared to the three months ended March 31, 2023. Animal Health Adjusted EBITDA increased $2.3 million due to gross profit from increased sales, partially offset by higher SG&A. Mineral Nutrition Adjusted EBITDA increased $0.8 million, driven by higher gross profit. Performance Products Adjusted EBITDA remained relatively the same. Corporate expenses increased $0.7 million, driven by increased employee-related costs.

### Adjusted provision for income taxes

The adjusted provision for income taxes was $5.7 million and $5.8 million for the three months ended March 31, 2024 and 2023, respectively. The adjusted effective income tax rates were 30.8% and 33.2% for the three months ended March 31, 2024 and 2023, respectively. The improvement in our adjusted effective income tax rate for the three months ended March 31, 2024 was driven by a favorable mix of pre-tax income.

### Adjusted net income

Adjusted net income of $12.7 million for the three months ended March 31, 2024, increased $1.1 million, or 9%, as compared to the prior year. Increased adjusted gross profit, driven by sales growth, was partially offset by higher adjusted SG&A and higher adjusted interest expense, net, with a partial benefit from a reduced adjusted provision for income taxes. Adjusted SG&A increased due to increased employee-related costs and adjusted interest expense, net, increased due to higher variable interest rates.

### Adjusted diluted earnings per share

Adjusted diluted earnings per share was $0.31 for the quarter, an increase of $0.02, or 9% as compared to the adjusted diluted earnings per share of $0.29 in the prior year.

### Comparison of nine months ended March 31, 2024 and 2023

### Net sales

Net sales of $744.5 million for the nine months ended March 31, 2024, increased $21.7 million, or 3%, as compared to the nine months ended March 31, 2023. Animal Health sales increased $31.9 million. Mineral Nutrition and Performance Products sales decreased $2.6 million and $7.6 million, respectively.

#### Animal Health

Net sales of $515.0 million for the nine months ended March 31, 2024, increased $31.9 million, or 7%. Net sales of MFAs and other increased $21.1 million, or 7%, due to increased volumes in all regions and higher demand for processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products decreased $6.1 million, or 5%, driven by decreased demand for domestic dairy and microbial products. Net sales of vaccines increased $16.9 million, or 23%, due primarily to poultry product introductions in Latin America, plus an increase in domestic demand.

#### Mineral Nutrition

Net sales of $181.6 million for the nine months ended March 31, 2024, decreased $2.6 million, or 1%, driven by lower average selling prices, partially offset by an increase in sales volume.

#### Performance Products

Net sales of $47.9 million for the nine months ended March 31, 2024, decreased $7.6 million, or 14%, driven by decreased demand for personal care product ingredients and industrial chemicals.

### Gross profit

Gross profit of $225.9 million for the nine months ended March 31, 2024, increased $4.4 million, as compared to the nine months ended March 31, 2023. Gross margin decreased 40 basis points to 30.3% of net sales for the nine months ended March 31, 2024, as compared to 30.7% for the nine months ended March 31, 2023 due to unfavorable product mix.

Animal Health gross profit increased $10.0 million as a result of higher product demand. Mineral Nutrition gross profit decreased $2.4 million, driven by lower sales volume and an increase in raw material costs. Performance Products gross profit decreased $2.7 million due to lower demand and unfavorable product mix. Acquisition-related cost of goods sold reduced gross profit by $0.5 million.

### Selling, general and administrative expenses

SG&A of $191.0 million for the nine months ended March 31, 2024, increased $17.6 million, or 10%, as compared to the nine months ended March 31, 2023. SG&A for the nine months ended March 31, 2024, included $10.7 million pension settlement costs, a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes paid from January 2013 through December 2015, acquisition-related costs of $0.5 million and $0.3 million of stock-based compensation, slightly offset by a gain from insurance proceeds of $0.3 million. SG&A for the nine months ended March 31, 2023, included $6.9 million of environmental remediation costs. Excluding these items, SG&A increased $9.0 million, or 5%.

Animal Health SG&A increased $5.6 million primarily due to an increase in employee-related costs and new product launches in Brazil. Mineral Nutrition SG&A remained relatively flat. Performance Products SG&A decreased $0.3 million, with a reduction in spending. Corporate expenses increased $3.7 million due to an increase in strategic investments and employee-related costs.

### Interest expense, net

Interest expense, net of $13.8 million for the nine months ended March 31, 2024, increased $3.0 million, or 27%, as compared to the nine months ended March 31, 2023, as a result of higher variable interest rates and increased debt levels, partially offset by higher returns on short-term investments.

### Foreign currency losses, net

Foreign currency losses, net for the nine months ended March 31, 2024, were $16.6 million, as compared to net losses of $4.6 million for the nine months ended March 31, 2023. Current period losses were driven by fluctuations in certain currencies relative to the U.S. dollar, primarily related to a major devaluation in Argentina.

### Provision for income taxes

The provision for income taxes was $2.8 million and $11.5 million for the nine months ended March 31, 2024 and 2023, respectively. The effective income tax rates were 63.1% and 35.3% for the nine months ended March 31, 2024 and 2023, respectively. The effective income tax rate for the nine months ended March 31, 2024, was unfavorably affected by the relatively greater effect of certain items such as GILTI on reduced pre-tax income. The provision for income taxes for the nine months ended March 31, 2024, included (i) a $1.2 million benefit related to the determination of whether a foreign tax is eligible for a U.S. foreign tax credit related to our fiscal year 2023, based on Internal Revenue Service (“IRS”) guidance provided subsequent to our fiscal year-end, (ii) a $0.5 million benefit related to the release of certain valuation allowances on non-U.S. companies and (iii) a $1.1 million expense from changes in uncertain tax positions related to prior years. The effective income tax rate, without these items, would have been 78.5% for the nine months ended March 31, 2024. The provision for income taxes for the nine months ended March 31, 2023, included a $0.9 million benefit related to exchange rate differences on intercompany dividends and a $0.2 million expense from changes in uncertain tax positions related to prior years. The effective income tax rate, without these items, would have been 37.5% for the nine months ended March 31, 2023.

### Net income

Net income of $1.7 million for the nine months ended March 31, 2024, decreased $19.4 million, as compared to net income of $21.1 million for the nine months ended March 31, 2023. Operating income decreased $13.2 million driven by higher SG&A, slightly offset by higher gross profit. SG&A increased by $17.6 million, which included pension settlement costs of $10.7 million, Brazil employment taxes of $4.2 million, acquisition-related costs of $0.5 million and stock-based compensation of $0.3 million, slightly offset by a gain from insurance proceeds of $0.3 million. Changes in interest expense, net and foreign currency losses resulted in a $3.0 million and $12.0 million reduction in income before income taxes, respectively. This was partially offset by a $8.7 million decrease in income tax expense.

### Adjusted EBITDA

Adjusted EBITDA of $77.8 million for the nine months ended March 31, 2024, decreased $2.6 million, or 3%, as compared to the nine months ended March 31, 2023. Animal Health Adjusted EBITDA increased $6.1 million, resulting from higher sales and increased gross profit, partially offset by higher SG&A. Mineral Nutrition Adjusted EBITDA decreased $2.5 million, due to decreased sales and gross profit. Performance Products Adjusted EBITDA decreased $2.5 million, driven by decreased sales and gross profit. Corporate expenses increased $3.7 million due to increased strategic investment and employee-related costs.

### Adjusted provision for income taxes

The adjusted provision for income taxes was $12.7 million and $17.7 million for the nine months ended March 31, 2024 and 2023, respectively. The adjusted effective income tax rates for the nine months ended March 31, 2024 and 2023, were 28.6% and 34.3%, respectively. The improvement in our adjusted effective income tax rate during the nine months ended March 31, 2024 was primarily driven by a favorable mix of pre-tax income.

### Adjusted net income

Adjusted net income of $31.7 million for the nine months ended March 31, 2024, decreased $2.1 million, or 6%, as compared to the prior year. The decrease was driven by higher adjusted SG&A and higher adjusted interest expense, partially offset by higher gross profit and a partial benefit from a reduced adjusted provision for income taxes. Adjusted SG&A increased due to increased strategic investments and employee-related costs and adjusted interest expense, net, increased due to higher variable interest rates.

### Adjusted diluted earnings per share

Adjusted diluted earnings per share was $0.78 for the nine months ended March 31, 2024, a decrease of $0.05, or 6%, as compared to the adjusted diluted earnings per share of $0.83 in the prior year.

### Analysis of financial condition, liquidity and capital resources

Net increase (decrease) in cash and cash equivalents was:

*(in thousands)*

| ​ ​ For the Periods Ended March 31 ​ Cash provided (used) by: | ​ ​ ​ | ​ ​ Nine Months 2024 ​ ​ | ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ | ​ ​ Change ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: |
| Operating activities | ​ | $59,165 | ​ | $(6,928) | ​ | $66,093 |
| Investing activities | ​ | (39,083) | ​ | (63,736) | ​ | 24,653 |
| Financing activities | ​ | (8,555) | ​ | 33,319 | ​ | (41,874) |
| Effect of exchange-rate changes on cash and cash equivalents | ​ | (2,583) | ​ | 335 | ​ | (2,918) |
| Net increase (decrease) in cash and cash equivalents | ​ | $8,944 | ​ | $(37,010) | ​ | $45,954 |

Certain amounts may reflect rounding adjustments.

Net cash provided (used) by operating activities was comprised of:

*(in thousands)*

| ​ ​ For the Periods Ended March 31 ​ | ​ ​ | ​ ​ Nine Months 2024 | ​ | ​ ​ 2023 | ​ | ​ ​ Change |
| --- | --- | --- | --- | --- | --- | --- |
| EBITDA | ​ | $45,283 | ​ | $68,890 | ​ | $(23,607) |
| Adjustments: |  | ​ ​ |  | ​ ​ |  | ​ ​ |
| Acquisition-related cost of goods sold | ​ | ​ 521 | ​ | ​ — | ​ | ​ 521 |
| Acquisition-related other | ​ | ​ 512 | ​ | ​ — | ​ | ​ 512 |
| Pension settlement cost | ​ | ​ 10,674 | ​ | ​ — | ​ | ​ 10,674 |
| Brazil employment taxes | ​ | ​ 4,202 | ​ | ​ — | ​ | ​ 4,202 |
| Insurance proceeds | ​ | ​ (274) | ​ | ​ — | ​ | ​ (274) |
| Stock-based compensation |  | ​ 296 |  | ​ — |  | ​ 296 |
| Environmental remediation costs | ​ | ​ — | ​ | ​ 6,894 | ​ | ​ (6,894) |
| Foreign currency losses, net |  | ​ 16,593 |  | ​ 4,629 |  | ​ 11,964 |
| Interest paid, net |  | ​ (13,018) |  | ​ (10,289) |  | ​ (2,729) |
| Income taxes paid |  | ​ (11,567) |  | ​ (16,163) |  | ​ 4,596 |
| Changes in operating assets and liabilities and other items |  | ​ 5,943 |  | ​ (60,889) |  | ​ 66,832 |
| Net cash provided (used) by operating activities | ​ | $59,165 | ​ | $(6,928) | ​ | $66,093 |

Certain amounts may reflect rounding adjustments.

#### Operating activities

Operating activities provided $59.2 million of net cash for the nine months ended March 31, 2024. Cash provided by net income, adjusted for the non-cash items, including depreciation and amortization, was $46.9 million. We paid $13.0 million of net interest expense and $11.6 million in income taxes, net. Cash provided in the ordinary course of business from changes in operating assets and liabilities and other items was $5.9 million. Accounts receivable provided $3.0 million of cash due to timing of sales and an improvement in days sales outstanding. Inventories used $5.9 million of cash due to increased raw material and production costs, and increased quantities on hand due to forecasted future demand and internal production schedules. Accounts payable provided $8.1 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $2.9 million, primarily due to timing of incurrence and payments for professional fees.

#### Investing activities

Investing activities used $39.1 million of net cash for the nine months ended March 31, 2024. Capital expenditures totaled $28.2 million, as we continue to invest in expanding production capacity and productivity improvements. Net purchases and maturities of our short-term investments used $8.5 million in cash. We acquired a business for $3.3 million, net of cash acquired.

#### Financing activities

Financing activities used $8.6 million of net cash for the nine months ended March 31, 2024. Net borrowings on our 2021 Revolver provided $24.0 million in cash. We paid $15.3 million in scheduled long-term debt maturities. Insurance premium financing and other short-term debt provided $2.7 million of cash, while we paid $5.4 million in insurance premium financing and other short-term debt. We paid $14.6 million in dividends to holders of our Class A common stock and Class B common stock.

#### Liquidity and capital resources

We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under the 2021 Revolver, will be sufficient to support our ongoing cash needs. We are aware of the current and potential future effects of the macroeconomic market conditions in the financial markets. At this time, we expect adequate liquidity for at least the next 12 months.

Our future cash is expected to be impacted by the Purchase Agreement entered with Zoetis Inc. and our intent to finance the transaction with new debt in the amount of $325.0 million. See “Notes to Consolidated Financial Statements – Subsequent Event – Agreement to Acquire an MFA product portfolio and related assets.”

We can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will comply with the terms of the covenants under the 2021 Credit Facilities based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or ability to obtain future financing or fund operations or investment opportunities. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources follow:

*(in thousands, except ratios)*

| ​ ​ As of ​ | ​ ​ | ​ ​ March 31, 2024 | ​ | ​ ​ June 30, 2023 |
| --- | --- | ---: | --- | ---: |
| Cash and cash equivalents and short-term investments | ​ | $98,748 | ​ | $81,281 |
| Working capital | ​ | 339,171 | ​ | 350,737 |
| Ratio of current assets to current liabilities | ​ | 3.13:1 | ​ | 3.28:1 |

We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

As of March 31, 2024, we had $165.0 million in outstanding borrowings under the 2021 Revolver and outstanding letters of credit and other commitments of $2.3 million, leaving $142.7 million available for further borrowings and letters of credit, subject to restrictions in our 2021 Credit Facilities.

We currently intend to pay quarterly dividends on our Class A common stock and Class B common stock, subject to approval from the Board of Directors. Our Board of Directors declared a cash dividend of $0.12 per share on Class A common stock and Class B common stock, payable on June 26, 2024. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions.

As of March 31, 2024, our cash and cash equivalents and short-term investments included $97.8 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries. Distributions may be subject to taxation by U.S. or non-U.S. taxing authorities.

### Contractual obligations

As of March 31, 2024, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report.

### Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

### General description of non-GAAP financial measures

### Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to reflect the results of our operations prior to considering certain income statement elements and to make financial and operating decisions. We calculate EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (a) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (b) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income and should not be considered as a measure of liquidity.

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
- our annual budgets are prepared on an Adjusted EBITDA basis; and
- other goal-setting and performance measurements are prepared on an Adjusted EBITDA basis.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of acquired intangibles, and does not provide a comparable view of our performance to other companies.

### Adjusted net income and adjusted diluted earnings per share

Adjusted net income and adjusted diluted earnings per share represent alternative views of performance and we believe investors’ understanding of our performance is enhanced by disclosing these performance measures. We report adjusted net income and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. We calculate adjusted net income as net income plus (i) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, (ii) amortization of acquired intangibles and other acquisition-related costs, such as accrued compensation and accrued interest, (iii) stock-based compensation, (iv) certain items that we consider to be unusual or non-recurring and (v) the income tax effect of pre-tax income adjustments and certain income tax items. Adjusted diluted earnings per share is calculated using the adjusted net income divided by the diluted weighted average number of shares. The adjusted net income and adjusted diluted earnings per share measures are not, and should not be viewed as, a substitute for GAAP reported net income.

Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measure that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of its non-standardized definition, adjusted net income and adjusted diluted earnings per share, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted net income and adjusted diluted earnings per share are presented to permit investors to more fully understand how management assesses performance.

### Certain significant items

Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis.

We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives, including employee separation costs, to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

### New accounting standards

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements—Summary of Significant Accounting Policies and New Accounting Standards.”

### Critical Accounting Policies

Our significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended June 30, 2023, included in our Annual Report on Form 10-K filed with the Securities Exchange Commission on August 30, 2023. There have been no significant changes in our critical accounting estimates since June 30, 2023.

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

- outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials;
- perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
- restrictions on the use of antibacterials in food-producing animals may become more prevalent;
- the potential FDA withdrawal of approval of our Mecadox® (carbadox) product;
- a material portion of our sales and gross profits are generated by antibacterials and other related products;
- competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development (“R&D”), production and other resources than we have;
- our business may be negatively affected by weather conditions and the availability of natural resources;
- the negative effects of a pandemic, epidemic, or outbreak of an infectious disease in humans, such as COVID-19; on our business, financial results, manufacturing facilities and supply chain, as well as our customers, protein processors and markets;
- climate change could have a material adverse impact on our operations and our customers’ businesses;
- actions of regulatory bodies, including obtaining approvals related to the testing, manufacturing and marketing of certain of our products;
- the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
- our ability to control costs and expenses;
- any unforeseen material loss or casualty;
- misuse or extra-label use of our products;
- exposure relating to rising costs and reduced customer income;
- heightened competition, including those from generics and those deriving from advances in veterinary medical practices and animal health technologies;
- unanticipated safety or efficacy concerns;
- our dependence on suppliers having current regulatory approvals;
- our raw materials are subject to price fluctuations and their availability can be limited;
- natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
- business interruption from political and social instability, including crime, civil disturbance, terrorist activities, outbreaks of disease and pandemics and armed conflicts, such as the ongoing armed conflicts between Russia and Ukraine and Israel and Hamas;
- terrorist attacks, particularly attacks on or within markets in which we operate, including the recent terrorist attack on Israel by Hamas militants and the ongoing related conflict;
- risks related to changes in tax rates and exposure;
- our ability to successfully implement our strategic initiatives;
- our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
- adverse U.S. and international economic market conditions, including currency fluctuations;
- failure of our product approval, R&D, acquisition and licensing efforts to generate new products;
- the risks of product liability claims, legal proceedings and general litigation expenses;
- the impact of current and future laws and regulatory changes, including risks related to the protection of our customers’ privacy and risks related to environmental, health and safety laws and regulations;
- modification of foreign trade policy may harm our food animal product customers;
- our dependence on our Israeli and Brazilian operations;
- impact of increased or decreased inventory levels at our direct customers or channel distributors;
- our substantial level of indebtedness and related debt-service obligations;
- restrictions imposed by covenants in our debt agreements;
- the risk of work stoppages; and
- other factors as described in “Risk Factors” in Item 1A of our Annual Report.

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

## Market risk

As filed, 1,306 characters.

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts and interest rate swaps as a means of hedging exposure to foreign currency risks and fluctuating interest rates, respectively. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. As of the date of this report, there were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

## Controls and procedures

As filed, 894 characters.

### Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based upon that evaluation as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective.

### Changes in Internal Control over Financial Reporting

There were no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarter ended March 31, 2024.

## Risk factors

As filed, 380 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in Item 1A of our Annual Report, which could materially affect our business, financial condition or future results.

There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.

Filed May 8, 2024.
Source: SEC EDGAR, the filing index for accession 0001558370-24-007340. Last ingested by Listed: Nov 4, 2026, 17:49 ET. No prices; not investment advice.